Inhibition of hepatic p63 ameliorates steatohepatitis with fibrosis in mice

• Main Authors: Marcos F. Fondevila (Author), Eva Novoa (Author), Uxia Fernandez (Author), Valentina Dorta (Author), Tamara Parracho (Author), Henriette Kreimeyer (Author), Maria Garcia-Vence (Author), Maria P. Chantada-Vazquez (Author), Susana B. Bravo (Author), Begoña Porteiro (Author), Alba Cabaleiro (Author), Mijra Koning (Author), Ana Senra (Author), Yara Souto (Author), Joanne Verheij (Author), Diana Guallar (Author), Miguel Fidalgo (Author), Abraham S. Meijnikman (Author), Natalia da Silva Lima (Author), Carlos Dieguez (Author), Maria J. Gonzalez-Rellan (Author), Ruben Nogueiras (Author)
• Format: Book
• Published: Elsevier, 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: p63 is a transcription factor involved in multiple biological functions. In the liver, the TAp63 isoform induces lipid accumulation in hepatocytes. However, the role of liver TAp63 in the progression of metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis is unknown. Meth...